

CURRICULUM VITAE

Hendrik Nolte, MD, PhD

90 Darren Drive
Basking Ridge, New Jersey 07920
Telephone: 908 432 4483
Personal email: hendriknolte@hotmail.com
Business email: hendrik.nolte@merck.com

Current Position

Section Head, Executive Director, Respiratory & Immunology, Merck Sharp and Dome

Education:

MD, PhD

14 years of clinical work experience in Internal Medicine/Pulmonology/Allergy
PhD Thesis Title: Mediator release from human mast cells and basophils

Pre-graduate clinical positions

1983 Department of Family Medicine, Practice & Emergency Services. Lions Gate
Hospital, Vancouver BC, Canada.

1983 Department of Allergy and Clinical Immunology,
University Hospital of Washington, Seattle, U.S.A.

Post-graduate positions

Intern & Resident	University Hospital Copenhagen, Denmark	1985-87
Ph.D.	University Hospital Aarhus, Denmark	1987-89
Fellow in Internal Medicine/ Allergy	University Hospital Copenhagen, Denmark	1998-99
Fellow in Pulmonology	University Hospital Copenhagen, Denmark	1999-01
Associate Professor/ Head of Pulmonary Ward	University Hospital Copenhagen, Denmark	1998-05

Current Licensure/Certification:

National Board of Medical Examiners	1985-
European Medical License	1993-
National Board of Internal Medicine	1997-
National Board of Pulmonary Medicine	2002-

Committees/Societies/Professional Affiliations: Fellow of AAAAI, Fellow of ACAAI

Lundbeck Diagnostics, Denmark

Medical Director 1988-1989

Managed allergy diagnostic R&D work, worked closely with regulatory affairs dept., part of a 4 member team of new business developments negotiating contracts with Japanese and U.S. pharmaceutical firms, clinical trials, new product development, information services, medical consultations, responsible for 5 direct reports.

Publications (Full text and peer reviewed):

1. Skov PS, Jensen PS, **Nolte H**, Mosbech H, & Norn S. Regulatory Role of Cell-Bound IgE on Histamine Release. - Drug Receptors and Dynamic Processes in Cells. Alfred Benzon Symposium 22. Editors: JS Schou, A Geisler, S Norn. pp. 245-254, Munksgaard 1986.
2. **Nolte H**, Skov PS, and Loft H. Stimulation of histamine synthesis from tumor cells by concanavalin and A 23187. *Agents and Actions*, 20: 291-294, 1987.
3. Skov PS, Norn S, Weeke B, and **Nolte H**. Impaired basophil histamine release from allergic patients. *Agents and Actions*, 20: 303-306, 1987.
4. **Nolte H**, Schiøtz PO, and Skov PS. A new glass-microfibre based Histamine Analysis for Allergy testing in Children. Results compared with Conventional Leukocyte Histamine release Assay, Skin Prick Test, Bronchial Provocation Test and RAST. *Allergy*, 24: 366-373, 1987.
5. **Nolte H**, Stafanger G, Skov PS, and Schiøtz PO. Passive sensitization of basophil leukocytes from a non-atopic person with plasma from allergic children. *Allergy*, 43: 32-38, 1988.
6. **Nolte H**, Pedersen L, and Mouridsen HT. Combined treatment of advanced malignant melanoma with coumarine and cimetidine. *Anti Cancer Research*, 7: 449-450, 1987.
7. Carstensen H, **Nolte H**, Hertz H, and Jensen T. Hypersensitivity reactions to Teniposide (VM-26) in children. *J. Clin. Oncol.* 5: 1491-1492, 1987.
8. **Nolte H**, Skov PS. Inhibition of basophil histamine release by Methotrexate. *Agents and Actions*, 23: 173-176, 1988.
9. **Nolte H**, Carstensen H, Hertz H. VM-26 (Teniposide) induced hypersensitivity and degranulation of basophils in children. *Am J Pediatr Hematol Oncol.* 10: 308-312, 1989.
10. **Nolte H**, Gjedde SB, Lindegaard-Madsen E, Berg J, Blomquist E, Mouridsen HT. Phase II study of Tauromustine in disseminated malignant melanoma. *Eur J Cancer Clin Oncol.* 25: 655-657, 1989.
11. **Nolte H**, Kruse A, Skov PS & Schiøtz PO. Passive sensitization of human intestinal mast cells. *Agents and Actions.* 27: 93-96, 1989.
12. **Nolte H**, Skov PS, Kruse A, Schiøtz PO. Histamine release from dispersed human intestinal mast cells. A method using biopsies from children and adults. *Allergy*, 44: 543-553, 1989.

13. **Nolte H**, Schiøtz PO, Kruse A, Skov PS. Comparison of intestinal mast cell and basophil histamine release in children with food allergic reactions. *Allergy*, 44: 554-565, 1989.
14. **Nolte H**, Spjeldnæs N, Kruse A, Windelborg B. Histamine release from patients with inflammatory bowel diseases. *Gut*, 31: 791-794, 1990.
15. **Nolte H**, Søderberg U, Thestrup-Pedersen K, Schiøtz PO. Histamine release from skin mast cells and basophils in patients with urticaria pigmentosa. *Acta Derm Venerol*, 70: 154-156, 1990.
16. **Nolte H**, Storm K, Schiøtz PO. Diagnostic value of a glass fiber based histamine analysis for allergy testing in children. *Allergy*, 45: 213-223, 1990.
17. Poulsen LK, **Nolte H**, Søndergaard I, Skov PS. Immunochemical cross reactivity between albumin and solid-phase adsorbed histamine. *Agents and Actions*, 30: 313-318, 1990.
18. Østergaard PA, Ebbesen F, **Nolte H**, Skov PS. Basophil histamine release test in the diagnosis of house dust mite and dander allergy of asthmatic children. *Allergy*, 45: 231-235, 1990.
19. **Nolte H**, Poulsen M, Schiøtz PO, Skov PS. Passive sensitization and histamine release of basophils: IgE and cellular factors regulating histamine release. *Allergy* 45: 427-435, 1990.
20. **Nolte H**, Herlin T, Stender Hansen U, Fogh K, Schiøtz PO. Histamine release from cord basophils. *Agents and Actions*, 29: 37-38, 1990.
21. Andersson M, **Nolte H**, Olsson M, Stahl Skov P, Pipkorn U. Measurement of histamine in nasal lavage fluid; comparison of a glass fiber based fluorometric method with two radioimmunoassays. *J. Allergy Clin. Immunol.*, 86: 815-820, 1990.
22. Andersson M, **Nolte H**, Baumgarten C, Pipkorn U. Suppressive effect of loratadine on the allergen-induced histamine release in the nose. *Allergy*, 46: 540-546, 1991.
23. Williams PB, **Nolte H**, Dolen WK, Koepke FW, Selner JC. The histamine content of allergen extracts. *J. Allergy Clin. Immunol.*, 89: 738-745, 1992.
24. Kleine-Tebbe J, Werfel S, Rødsgaard D, **Nolte H**, Skov PS, Wahn U, Kunkel G. Comparison of fiber glass-based histamine assay with a conventional automated fluorometric histamine assay, case history, skin prick test, and specific serum IgE in patients with milk and egg allergic reactions. *Allergy*, 48:49-53, 1993.

25. Phillips MK, Manning TO, **Nolte H**, Bevier DE. Cutaneous histamine reactivity, histamine content of commercial allergens, and the potential for false-positive skin test reactions in dogs. *J. Am. Vet. Med. (JAVMA)*, 203: 1288-1292, 1993.
26. Babakhin AA, DuBuske LM, Wheeler AW, Stockinger B, **Nolte H**, Andreev SM, Guschin IS, Khaitov RM, Petrov RV. Immunological properties of allergen chemically modified with synthetic copolymer of N-vinylpyrrolidone and maleic anhydride. *Allergy Asthma Proc* 16: 261-268, 1995.
27. Laffer S, Spitzauer S, Susani M, Pairleithner H, Schweiger C, Gronlund H, Pauli G, Ishii T, **Nolte H**, Ebner C, Schon AH, Kraft D, Eicher HG, Valenta R. Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. *J Allergy Clin Immunol* 1996; 98: 652-658.
28. Nissen D, Petersen LJ, Skov PS, Karlsmark T, Vejlsgaard G, Poulsen LK, Jarløv JO, Karlsmark T, **Nolte H**. IgE binding components of staphylococcal enterotoxins in patients with atopic dermatitis. *Ann Allergy Asthma Immunol*, 1997, 79: 403-8.
29. **Nolte H**, DuBuske LM. Performance Characteristics of a new automated EIA for the measurement of Specific IgE. Summary of the Probability Outcomes Comparing Results of Allergen Skin Testing to Results Obtained with the HYTEC System and CAP System. *Ann Allergy*, 1997; 79: 27-34.
30. Gushchin IS, Babakhin AA, Andreev SM, Wheeler AW, Stockinger R, **Nolte H**, DuBuske LM. Modulation of Histamine Release Activity and T-cell Reactivity by Chemically Modified Allergen. *Russian Journal of Immunology* 1997; 2: 112-114.
31. Babakhin A, Majoul A, **Nolte H**, DuBuske LM. In vivo and In vitro Immunomodulation induced by the extract of the mycelium fungus *Polyporus Squamosus*. *Allergy Asthma Proceedings* 1997; 18: 301-310.
32. Guschin IS, Babakhin AA, Andrew SM, Wheeler AW, Stockinger B, **Nolte H**. Dissociation of histamine releasing activity and T-cell reactivity of allergen conjugated with synthetic polymer. *Inflamm Res* 1997 Suppl 1: 67-68.
33. Nissen D, Pedersen LJ, Esch R, Svejgaard E, Stahl Skov P, **Nolte H**. IgE-sensitization to cellular and culture filtrates of fungal extracts in patients with atopic dermatitis. *Ann Allergy Asthma Immunol*, 1998; 81: 247-255.
34. Nissen D, Petersen LJ, **Nolte H**, Permin H, Melchior N, Stahl Skov P. Measurement of histamine release from human lung tissue ex vivo by microdialysis technique. *Inflamm Research* 1998; 47: 501-505.

35. Nissen D, **Nolte H**, Permin H, Heinig J, Stahl Skov P, Norn S. Evaluation of IgE-sensitization to fungi in HIV-infected subjects with eczematous skin reactions. *Ann Allergy Asthma Immunol* 1999; 83:153-159.
36. Yamada S, **Nolte H**, Zychlinsky E. Identification and characterization of allergens in two species of tuna fish. *Ann Allergy Asthma Immunol* 1999; 82: 395-400.
37. DuBuske LM, Babahkin A, Cieslewicz G, **Nolte H**, Sheffer AL. Clinical Assessment of Latex Allergy among Hospital Health Care Providers. *Int Arch Allergy Immunol* 1999; 118: 253-254.
38. Babakhin AA, **Nolte H**, DuBuske LM. Effect of misoprostol on the secretion of histamine from basophils of whole blood. *Ann Allergy Asthma Immunol* 2000, 84: 361-365.
39. Nielsen PS, Nissen D, Skov P, Cieslewics G, Markov A, Babahkin A, Zakirova I, Gots T, DuBuske LM, Sheffer A, **Nolte H**. Assessment of IgE allergen specificity among latex-allergic health care workers: review of IgE-binding components of various latex extracts. *Ann Allergy Asthma Immunol* 2000; 85: 489-494.
40. Anhøj C, Backer V, **Nolte H**. Diagnostic evaluation of patients with oral allergy syndrome. *Allergy*, 2001; 56: 548-52.
41. Porsbjerg C, von Linstow ML, Nepper-Christensen S, **Nolte H**, Korsgaard J, Backer V and the greenlandic population group. Allergen sensitization and allergen exposure in Greenlander Inuit residing in Denmark or Greenland. *Resp Med* 2002; 96: 736-44
42. Kowal, Krzysztof Buske, Lawrence M. Du **Nolte, Hendrik**. Allergen immunotherapy: how to get the best results; benefits may persist for years after therapy is discontinued. *J Respir Dis*. 2002;23(5):311-317)
43. **Nolte H**, Babakhin A, Babanin A, Bakhustavili V, Du Buske LM. Prevalence of Skin Test Reactions to Natural Rubber Latex in Hospital Personnel in Russia and Eastern Europe. *Ann Allergy Asthma Immunol*. 2002, 89: 452-456.
44. Christensen SN, Backer V, DuBuske LM, **Nolte H**. In Vitro Diagnostic Evaluation of Patients with Inhalant Allergies. Summary of probability outcomes comparing results of CLA and CAP Specific IgE Test Systems. *Int Arch Asthma Allergy Immunol* 2003; 24: 253-258.
45. Babakhin AA, Louss LV, Zakharov SY, **Nolte H**, Swenson MC, Williams PB, DuBuske LM. Allergy to latex among health care workers of Moscow medical institutions. *Physiology and Pathology of Immune System* 2004;Vol 5:5-14.

46. K Kowal, **H Nolte**, P Stahl Skov, and L Du Buske. Effect of allergen specific immunotherapy (SIT) on recombinant human interleukin 3 (rhIL-3) mediated amplification of allergen induced basophil histamine release. *Int Arch Asthma Allergy Immunol* 2005.
47. **H. Nolte**, S Nepper-Christensen, V Backer. Unawareness and undertreatment of asthma and rhinitis in a general population. *Respir Med.* 2006; 100:354-62
48. Rasmussen LM, Phanareth K, **Nolte H**, Backer V. Internet-based monitoring of asthma: A long-term, randomized clinical study of 300 asthmatic subjects. *J Allergy Clin Immunol* 2005; 115:1137-42.
49. Winther L, Arnved J, Malling HJ, **Nolte H**, Mosbech H. Side effects of allergen specific immunotherapy. A prospective multi-centre study. *Clin Exp Allergy* 2006; 36: 254-260.
50. V. Backer, S. Nepper-Christensen, **H. Nolte**. Quality of care in patients with asthma and rhinitis treated by respiratory specialists and primary care physicians: a 3-year randomized and prospective follow-up study. *Ann Allergy Asthma Clin Immunol.* 2006; 97: 490-496.
51. C. Porsbjerg, L. Rasmussen, **H. Nolte**, V. Backer. Association of airway hyperresponsiveness with reduced quality of life in patients with moderate to severe asthma. *Ann Allergy Asthma Clin Immunol.* 2006; 98: 44-50.
52. Backer V, Harmsen L, Lund T, Pedersen L, Porsbjerg C, Rasmussen L, Thomsen SF, **Nolte H**. A 3-year longitudinal study of asthma quality of life in undiagnosed and diagnosed asthma patients. *Int J Tuberc Lung Dis.* 2007; 11(4):463-9
53. Molgaard E, Thomsen SF, Lund T, Pedersen L, **Nolte H**, Backer V. Differences between allergic and nonallergic rhinitis in a large sample of adolescents and adults. *Allergy.* 2007;62:1033-7.
54. Backer V, Nepper-Christensen S, **Nolte H**. Quality of care in patients with asthma and rhinitis treated by respiratory specialists and primary care physicians: a 3-year randomized and prospective follow-up study. *Ann Allergy Asthma Immunol.* 2006; 97: 490-6.
55. Aslund N, Thomsen SF, Mølgaard E, **Nolte H**, Backer V. Changes in skin test reactivity among adults with atopic disease: a 3-year prospective study. *Ann Allergy Asthma Immunol.* 2008;101:524-8.
56. Backer V, **Nolte H**, Pedersen L, Dam N, Harving H. Unawareness and undertreatment of asthma: follow-up in a different geographic area in Denmark. *Allergy.* 2009; 64:1179-84.
57. Knudsen TB, Thomsen SF, **Nolte H**, Backer V. A population-based clinical study of allergic and non-allergic asthma. *J Asthma.* 2009; 46:91-4.
58. Harmsen L, **Nolte H**, Backer V. The effect of generalist and specialist care on quality of life in asthma patients with and without allergic rhinitis. *Int Arch Allergy Immunol.* 2010;152:288-94.

59. Hansen JW, Thomsen SF, **Nolte H**, Backer V. Rhinitis: a complication to asthma. *Allergy*. 2010;65:883-8.
60. Wyrwich KW, Ireland AM, Navaratnam P, **Nolte H**, Gates DF. An Assessment of Change in Asthma Control among Adolescents and Adults with Persistent Asthma In Mometasone Furoate/Formoterol Fumarate Clinical Trials. *J Asthma*. 2010;48:48-56.
61. Maspero JF, **Nolte H**, Chérrez-Ojeda I. Long-Term Safety of Mometasone Furoate/Formoterol Combination for Treatment of Patients with Persistent Asthma. *J Asthma*; 2010 Sep 28.
62. Weinstein SF, Corren J, Murphy K, **Nolte H**, White M. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. *Allergy Asthma Proc*. 2010; 31:280-9.
63. Nathan RA, **Nolte H**, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. *Allergy Asthma Proc*. 2010; 31:269-79.
64. Blaiss M, Maloney J, **Nolte H**, Gawchick S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. *J Allergy Clin Immunol* 2011; 127:64-71.
65. Nelson HS, **Nolte H**, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. *J Allergy Clin Immunol* 2011; 127:72-80.
66. Wyrwich KW, Ireland AM, Navaratnam P, **Nolte H**, Gates DF Jr. Validation of the AQLQ12+ among adolescents and adults with persistent asthma. *Qual Life Res*. 2011; 20:903-12
67. Wyrwich KW, Khan SA, Navaratnam P, **Nolte H**, Gates DF Jr. Validation and agreement across four versions of the asthma control questionnaire in patients with persistent asthma. *Respir Med*. 2011;105:698-712.
68. Meltzer EO, Kuna P, **Nolte H**, S Nayak A, Laforce C. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. *Eur Respir J*. 2012; 39:279-89
69. Bernstein DI, Hebert J, Cheema A, Murphy KR, Chérrez-Ojeda I, Matiz-Bueno CE, Kuo W, **Nolte H**. Efficacy and Onset of Action of Mometasone Furoate/Formoterol and Fluticasone Propionate/Salmeterol Combination Treatment in Subjects With Persistent Asthma. *Allergy, Asthma & Clinical Immunology* 2012; 39: 279-89.
70. Nayak AS, Atiee GJ, Dige E, Maloney J, **Nolte H**. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. *Allergy Asthma Proc*. 2012; 33:404-410.

71. Nelson H, Blaiss M, **Nolte H**, Würtz Ø, Andersen JS, Durham SR. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. *Allergy* 2013;68:252-5.
72. **Nolte H**, Pavord I, Backer V, Spector S, Shekar T, Gates D, Nair P, Hargreave F. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma. *Respir Med.* 2013;107(5):656-64.
73. Creticos PS, Maloney J, Bernstein DI, Casale T, Kaur A, Fisher R, Liu N, Murphy K, Nekam K, **Nolte H**. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. *J Allergy Clin Immunol* 2013;131:1342-9.
74. **Nolte H**, Hébert J, Berman G, Gawchik S, White M, Kaur A, Liu N, Lumry W, Maloney J. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. *Ann Allergy Asthma Immunol* 2013;110:450-456.
75. Nelson H, Blaiss M, **Nolte H**, Wurtz SØ, Andersen JS, Durham SR. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. *Allergy* 2013; 68: 252–255.
76. Berger WE, Bensch GW, Weinstein SF, Skoner DP, Prenner BM, Shekar T, **Nolte H**, Teper AA. Bronchodilation with mometasone furoate/formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma. *Pediatr Pulmonol* 2014; 49(5): 441-450
77. Maloney J, Bernstein DI, Nelson H, Creticos P, Hébert J, Noonan M, Skoner D, Zhou Y, Kaur A, **Nolte H**. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. *Ann Allergy Asthma Immunol* 2014; 112: 146-153.
78. Durham SR, Nelson HS, **Nolte H**, Bernstein BI, Creticos PS, Li Z & Andersen JS. Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. *Allergy* 2014; 69(5): 617-623
79. Calderon MA, Bernstein DI, Blaiss M, Andersen JS, **Nolte H**. A Comparative Analysis of Symptom and Medication Scoring Methods Used in Clinical Trials of Sublingual Immunotherapy for Seasonal Allergic Rhinitis. *Clin Exp Allergy* 2014; 44:1228-1239.
80. Maspero J, Cherrez I, Doherty DE, Tashkin DP, Kuna P, Kuo W, Gates D, **Nolte H**, Chylack LT. Appraisal of Lens Opacity with Mometasone Furoate/Formoterol Fumarate Combination in Patients with COPD or Asthma. *Respir Med* 2014; 108(9):1355-1362.
81. **Nolte H**, Amar N, Bernstein DI, Lanier BQ, Creticos P, Berman G, Kaur A, Hébert J, Maloney J. Safety and tolerability of a short ragweed sublingual immunotherapy tablet. *Ann Allergy Asthma Immunol.* 2014;113(1):93-100.
82. Kim H, Wasserman S, Hébert J, Blaiss M, Nelson H, Creticos P, Kaur A, Maloney J, Li Z, **Nolte H**. Efficacy and safety of ragweed sublingual immunotherapy in

- Canadian patients with allergic rhinoconjunctivitis. *Allergy Asthma & Clinical Immunology* 2014, 10:55.
83. Hébert J, Blaiss M, Wasserman S, Kim H, Creticos P, Maloney J, Kaur A, Li Z, Nelson H, **Nolte H**. The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children. *Allergy, Asthma & Clinical Immunology* 2014, 10:53.
 84. Maloney J, Durham S, Skoner D, Dahl R, Bufe B, Bernstein D, Murphy K, Wasserman S, Berman G, White W, Kaur A and **Nolte H**. Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma. *Allergy* 2015, 70(3): 302-309.
 85. **Nolte H**, Maloney J, Nelson HS, Bernstein DI, Lu S, Li Z, Kaur A, Ziegelmayer P, Ziegelmayer R, Lemell P, Horak F. Onset and Dose-related Efficacy of House Dust Mite Sublingual Immunotherapy Tablet in an Environmental Exposure Chamber. *J Allergy Clin Immunol* 2015

Reviews (*peer review*'ed)

86. **Nolte H**. Histamine release from human intestinal mast cells and basophil leukocytes. In vitro studies and their clinical application. Medical Thesis University of Copenhagen 1992, FADL, ISBN 87-7749-083-5.
87. **Nolte H**. Histamine release in food allergy. *Immunol Allergy Practice* 12: 374-379, 1990.
88. **Nolte H**. Leukocyte histamine release test in clinical allergy. *Clinical Immunology* 12: 1-10, 1992.
89. **Nolte H**. Update: Clinical aspects of basophil histamine release. *Immunol Allergy Pract.* 14: 255-263, 1992.
90. **Nolte H**. The clinical utility of basophil histamine release. *Allergy Proceedings* 14: 251-254, 1993.
91. **Nolte H**. Allergens. *Current Opinion in Otolaryngology & Head and Neck Surgery.* 2: 112-117, 1994.
92. **Nolte H**. The Role of Mast Cells and Basophils in Immunoregulation. *Allergy Asthma Proc.* 17: 17-21, 1996.
93. **H. Nolte**. Purified natural versus recombinant birch pollen allergens for diagnosis of pollen allergy and oral food allergy. *J Allergy Soc South Africa* 10: 29, 1997.
94. **Nolte H**. Allergen Extracts, dosing, efficacy and safety of immunotherapy. *Int. Rev. Allergol Clin Immunol* 1999; 5: 184-188
95. **Nolte H, Backer V, Porsbjerg C**. Environmental causes for the increase in

- allergic diseases. *Ann Allergy Asthma Immunol.* 2001; 87:7-11.
96. Kowal K, Du Buske LM, **Nolte H.** Allergen Immunotherapy: How to get the best results. *J Respir Dis* 2002; 23: 311-317
 97. Cox L, Linnemann DL, **Nolte H,** Finegold I, Nelson H. Sublingual Immunotherapy: A Comprehensive Review. *J Allergy Clin Immunol* 2006; 117: 1021-35.
 98. Lee S, **Nolte H,** Benninger M. Clinical considerations in the use of sublingual immunotherapy for allergic rhinitis. *Am J Rhinol Allergy* 2015;29:106-114.

Books

99. S. Yamada, E. Zychlinsky, and **H. Nolte.** Identifying allergens in fish. pages 85-94; Chap. 6 in: Safety and quality issues in fish processing, Woodhead Publishing Co. edited by A. Bremner.
100. **H. Nolte,** K. Kowal, L. DuBuske. Allergy diagnosis using in vivo and in vitro allergy tests. In *UpToDate*, 2002-

Letters

101. Carstensen H, **Nolte H,** Hertz H: Teniposide induced hypersensitivity reactions in children and possible underlying mechanisms. *Lancet*, 2: 55, 1989.
102. **Nolte H.** Optimal maintenance dose immunotherapy based on major allergen content or potency labeling. *Allergy* 1997; 53: 99-101
103. **Nolte H,** Harving H, Backer V. Treatment of severe asthma with anti-immunoglobulin E (Omalizumab). A new possibility in pulmonary medicine. *Ugeskr Laeger.* 2007, 10;169:4366-7. Danish.

Other publications

104. Carstensen H, **Nolte H,** & Hertz H: Current status of the epipodophyllotoxins (VM26 and VP16) in childhood oncology. In: *Vepesid and Vumon. A status report.* Bristol Myers 1988.
105. **Nolte H:** In vitro diagnosis of food allergy in children, p 61-66. *Food allergy/Intolerance.* Janssenpharma A/S 1989.
106. **Nolte H.** The diagnostic use of histamine measurement. *Histamine Symposium. Clinical and experimental aspects.* Referencelab Comm. p55-61, 1994.
107. **Nolte H.** Behandling med leukotrien-antagonister. *Praktisk*

Lægemiddelinformation, no. 3, 1997.

108. **Nolte H.** "Cave Penicillin". Praktisk Lægemiddelinformation, no. 8, 1998
109. **Nolte H, Backer V, Vejlø F.** Lær at leve med kronisk obstruktiv lungesygdom. Et lære redskab for patienter og pårørende. Udgivet af Boehringer Ingelheim, 2002.

Scientific Lectures

More than 600 national and international lectures and presentations.